Merck is facing an awkward encore as one of the worst-performing blue chip stocks in 2025, sliding 23.3% year-to-date.

On the heels of President Donald Trump’s Monday announcement of an executive order that will slash prescription drug prices ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Merck ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

The firm is studying the combination in the first-line setting for head and neck cancer patients who had a PD-L1 combined positive score of less than 1.

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase ...

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...